Eli Lilly and Co Analyst Ratings
Halozyme Downgraded at Piper Sandler Despite Guidance Raise
Wedbush Adjusts Price Target on Biogen to $215 From $219
Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating
Biogen Analyst Ratings
HSBC Adjusts Price Target on Merck & Co. to $130 From $118, Keeps Hold Rating
AbbVie Analyst Ratings
Merck & Co Analyst Ratings
Johnson & Johnson Analyst Ratings
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
Strong Financial Outlook and Strategic Initiatives Underpin Buy Rating for AbbVie
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Gilead Sciences (GILD) and Sanofi (OtherSNYNF)
Hold Rating on Gilead Sciences Amid Trodelvy Trial Setbacks and Future Uncertainties
Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)
Balanced Outlook Amidst Strategic Shifts: Pfizer's Hold Rating Explained
Pfizer's Acoramidis Shows Promising Survival Trends: A Buy Rating Endorsement
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cellectis SA (CLLS) and Sanofi (OtherSNYNF)
Analysts Are Bullish on Top Healthcare Stocks: Sanofi (SNYNF), Agios Pharma (AGIO)
AstraZeneca Analyst Ratings